Scinai Immunotherapeutics Ltd. (SCNI)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue Annual

0 500K 1M 1.5M FY24: 658K FY25: 1.3M FY24 FY25

Gross Profit Annual

-3M -2M -1M 0 1M 2M 3M FY24: -580K FY25: -2.7M FY24 FY25

Operating Income Annual

-12M -8M -4M 0 4M 8M 12M FY21: -10.9M FY22: -11.1M FY23: -9.7M FY24: -8.6M FY25: -7.5M FY21 FY22 FY23 FY24 FY25

Net Income Annual

-10.5M -7M -3.5M 0 3.5M 7M 10.5M FY17: -10M FY20: -1.4M FY21: -8.2M FY22: -5.8M FY23: -6.5M FY24: 4.8M FY25: -8.3M FY17 FY20 FY21 FY22 FY23 FY24 FY25

Cost of Revenue Annual

0 1.5M 3M 4.5M FY24: 1.2M FY25: 4M FY24 FY25

Operating Cash Flow Annual

-24M -16M -8M 0 8M 16M 24M FY17: -2.9M FY20: -22.6M FY21: -7.4M FY22: -7.3M FY23: -9.4M FY24: -6.3M FY25: -6M FY17 FY20 FY21 FY22 FY23 FY24 FY25

Free Cash Flow Annual

-27M -18M -9M 0 9M 18M 27M FY17: -4.2M FY20: -24.5M FY21: -7.6M FY22: -8.1M FY23: -10M FY24: -6.3M FY25: -6.1M FY17 FY20 FY21 FY22 FY23 FY24 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 3.5B 7B 10.5B FY16: 135.1M FY17: 201M FY18: 261.4M FY19: 326.7M FY20: 443.3M FY21: 564.6M FY22: 754.1M FY23: 1.6B FY24: 3.2B FY25: 9.3B FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.